(Q44642230)

4 December 2017

title

Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes (English)

1 reference

4 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

28 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

28 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

28 March 2024

author name string

Chang TK

4

1 reference

4 December 2017

P. C. Ho

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14597963

28 March 2024

F. S. Abbott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14597963

28 March 2024

U. M. Zanger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14597963

28 March 2024

T. K H. Chang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14597963

28 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14597963

28 March 2024

publication date

1 January 2003

1 reference

full work available at URL

4 December 2017

https://www.nature.com/articles/6500210.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14597963

https://www.nature.com/articles/6500210.pdf

28 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

https://www.nature.com/articles/6500210

28 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

The Pharmacogenomics Journal

28 March 2024

published in

1 reference

4 December 2017

volume

3

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

335-342

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500210

4 December 2017

exact match

0 references

cites work

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Valproate hepatotoxicity syndrome: hypotheses of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Cytochrome P450 isozymes and antiepileptic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500210

7 January 2021

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

18

1 reference

https://api.crossref.org/works/10.1038/SJ.TPJ.6500210

28 March 2024

Identifiers

1 reference

Dimensions Publication ID

4 December 2017

1021703020

0 references

1 reference